Innoviva, Inc. (Nasdaq: INVA) (Innoviva), a diversified holding company with a portfolio of royalties and other healthcare assets, today announced that Nasdaq has halted trading of Innovivas common stock. The U.S. Food and Drug Administrations (FDAs) Antimicrobial Drugs Advisory Committee is...

Innoviva (NASDAQ:INVA Get Rating) had its price objective cut by The Goldman Sachs Group from $15.00 to $13.00 in a research report report published on Friday, Benzinga reports. They currently have a neutral rating on the biotechnology companys stock. Several other equities analysts ...

Six abstracts selected for presentation, including three oral presentationsWALTHAM, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc., a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, and wholly owned ...

Innoviva, Inc. (Nasdaq: INVA) (Innoviva), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of La Jolla Pharmaceutical...

Qube Research Technologies Ltd raised its holdings in Innoviva, Inc. (NASDAQ:INVA Get Rating) by 9.3% in the first quarter, according to its most recent Form 13F filing with the Securities Exchange Commission. The fund owned 51,432 shares of the biotechnology companys ...